Indian regulators over the weekend included some popular cough syrups containing codeine in a drug ban in what was deemed an effort to tighten up the nation's supply chain of opiates to fight smuggling and drug addiction. But the action by the Drug Controller General of India has unleashed a firestorm from Western drugmakers that dominate that market.
Given the high price of Gilead Sciences' hepatitis C cure Harvoni, it wasn't going to be long before it was targeted by counterfeiters. Now fakes have shown up in Switzerland and Israel.
One way for a drug wholesaler to strengthen its position in the supply chain is to own the drugstores that sell its meds. That is what drug distribution giant McKesson says it will do in Canada with a $2.23 billion (C$3 billion) deal for a leading pharmacy chain there.
A Chinese drugmaker has caught a break from the FDA, which needs its help in the face of a shortage of a chemo drug often used to treat AIDS-related Kaposi's sarcoma.
More woes for the U.S. supply of saline solution as Baxter International announced another voluntary recall of its products. This time, two lots of intravenous solutions have been recalled due to the presence of particulate matter after a customer complained of an insect found in the product, the FDA said.
Sanofi continues to come under pressure from health groups who say the drugmaker has ceased manufacturing BCG and created a global shortage of the vaccine used to treat tuberculosis and bladder cancer.
William Scully, one of two owners of Medical Device King based in New York, was convicted on charges that he sold more than $17 million worth of fake or unapproved drugs that were manufactured overseas.
Last month, four U.S. senators asked the FTC to investigate "possible illegal collusion" by saline solution manufacturers to determine whether they had been unfairly cashing in on a two-year shortage. But saline is only one of hundreds of hospital generic injectable drugs whose prices have soared in the last 8 years, And given the current state of affairs in the business, it is a situation unlikely to change.
Perrigo, in an effort to hive off $175 million a year in costs, is laying off 6% of its workforce, among other steps.
The FDA and the Department of Justice have taken down a couple more of the 33 players indicted in a massive drug diversion scam that undermined the U.S. pharma supply chain.